Maravai Lifesciences Holdings (MRVI) Liabilities and Shareholders Equity (2020 - 2026)

Maravai Lifesciences Holdings' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $713.2 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 25.69% year-over-year to $713.2 million; the TTM figure through Mar 2026 stood at $3.2 billion (down 31.13% YoY), while the FY2025 annual figure was $770.6 million, down 23.57% from the prior year.
• Liabilities and Shareholders Equity was $713.2 million for Q1 2026 at Maravai Lifesciences Holdings, down from $770.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.3 billion in Q1 2023 to a low of $713.2 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $1.6 billion across 5 years, with a median of $1.4 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity surged 51.15% in 2022, then sank 43.63% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.3 billion in 2022, then plunged by 34.83% to $1.5 billion in 2023, then slumped by 32.22% to $1.0 billion in 2024, then retreated by 23.57% to $770.6 million in 2025, then fell by 7.44% to $713.2 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $713.2 million (Q1 2026), $770.6 million (Q4 2025), and $849.2 million (Q3 2025), per Business Quant data.